SCHEMBL23826437

SCHEMBL23826437

CC(C)(CN(C(=O)O)C(C)(C)C)C1CCNCC1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA5 P31644 3/20 0.34
GABRB2 P47870 3/20 0.34
GABRA1 P14867 2/20 0.34
GABRA4 P48169 2/20 0.34
GABRP O00591 1/20 0.34
GABRD O14764 1/20 0.34
TSHR P16473 1/20 0.34
GABRB1 P18505 1/20 0.34
GABRG2 P18507 1/20 0.34
GABRB3 P28472 1/20 0.34
GABRA3 P34903 1/20 0.34
GABRA2 P47869 1/20 0.34
GABRE P78334 1/20 0.34
PMP22 Q01453 1/20 0.34
GABRA6 Q16445 1/20 0.34
GABRG1 Q8N1C3 1/20 0.34
GABRG3 Q99928 1/20 0.34
GABRQ Q9UN88 1/20 0.34
ARG1 P05089 1/20 0.34
ARG2 P78540 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL927784 0.76 GABRA5 (0.39) GABRA5GABRB2GABRA1GABRA4GABRP
SCHEMBL345654 0.75 GABRA5 (0.38) GABRA5GABRB2GABRA1GABRA4GABRP
SCHEMBL4000253 0.72
SCHEMBL27166484 0.72 ITGB3 (0.41) GABRA5GABRB2GABRA1GABRA4CPN1
Acetic Acid SCHEMBL10487370 0.72 GABRA5 (0.39) GABRA5GABRB2GABRA1GABRA4GABRP
SCHEMBL2955097 0.71 CPN1 (0.39) GABRA5GABRB2GABRA1GABRA4GABRP
SCHEMBL3613801 0.70 SLC6A1 (0.49) GABRA5GABRB2GABRA1GABRA4TSHR
SCHEMBL222368 0.70 SLC6A1 (0.49) GABRA5GABRB2GABRA1GABRA4TSHR
SCHEMBL222367 0.70 SLC6A1 (0.49) GABRA5GABRB2GABRA1GABRA4TSHR
SCHEMBL4000139 0.69 GNAI3 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220024921-A1 1,3,4-OXADIAZOLONE COMPOUND AND PHARMACEUTICAL NIPPON SHINYAKU CO., LTD. (JP) 2022-01-27 US disclosed
EP-3882239-A1 1,3,4-OXADIAZOLONE COMPOUND AND MEDICINE Nippon Shinyaku Co., Ltd. (JP) 2021-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220024921-A1 1,3,4-OXADIAZOLONE COMPOUND AND PHARMACEUTICAL PIM1, PIM3, PIM2 GABRA5 4036/4885GABRB2 4589/4885GABRA1 4129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.